Actinium Pharmaceuticals, Inc. (ATNM): Sloan-kettering Cance Memorial , 10% owner of Actinium Pharmaceuticals, Inc. sold 21,990 shares on Jul 8, 2016. The Insider selling transaction was reported by the company on Jul 12, 2016 to the Securities and Exchange Commission. The shares were sold at $1.80 per share for a total value of $39,582.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 7, 2016, Sloan-kettering Cance Memorial (10% owner) sold 20,840 shares at $1.82 per share price.On Apr 18, 2016, C. David Nicholson, (director) purchased 5,000 shares at $2.00 per share price.Also, On Apr 18, 2016, Sergio Traversa (director) purchased 3,000 shares at $2.02 per share price.On Apr 18, 2016, Sandesh Seth (director other) purchased 15,000 shares at $2.00 per share price.
Actinium Pharmaceuticals Inc (ATNM) witnessed a volatile trading activity on Monday Jul 11, 2016 and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.8 and reached the intraday high at $1.8001. The bulls started the profit booking and pushed the shares to intraday low of $1.75. The trading session was marked by a volume range of 2,07,894 shares exchanging hands. The 52-week high of the shares is $3.5 and the 52-week low is $1.52. The market cap of the company stands at $84 M and there are 4,69,50,180 shares in public circulation.
Actinium Pharmaceuticals Inc. (Actinium) is a biopharmaceutical company engaged in developing therapies for diseases using its alpha particle immunotherapy (APIT) platform and other related technologies. The Company’s products include Actimab-A an antibody-drug construct containing actinium 225 (Ac-225) and Iomab-B an antibody-drug construct containing iodine 131 (I-131). As of December 31 2014 Actinium’s Actimab-A was in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. As of December 31 2014 the Company had four product candidates in clinical trials: Actimab-A (HuM195-Ac-225) Iomab-B (BC8-I-131) BC8-Y-90 and BC8-SA. As of December 31 2014 BC8-Y-90 and BC8-SA were in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center (FHCRC).